Posts of Core One Admin
Company News
Core One Labs’ Upgrades to OTCQB Venture Market
April 06, 2022
Vancouver, British Columbia, Canada – April 6, 2022 – Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”...
Read more
Company News
Core One Labs’ Akome Receives Positive Results from Bioassay Studies Will Look to Advance its Psychedelic Based Formulations
April 02, 2022
Vancouver, British Columbia, Canada – April 2, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”)...
Read more
Company News
Core One’s Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan’s Mass Production Capabilities
March 15, 2022
Vancouver, British Columbia, Canada – March 15, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin
March 12, 2022
Successful Breakthrough of Biosynthetic Psilocybin Production Method Progressing Quickly
Vancouver, British Columbia, Canada – March 12, 2022 – Core One Labs...
Read more
Company News
Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations
March 04, 2022
Vancouver, British Columbia, Canada – March 4, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the...
Read more
Company News
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)
March 03, 2022
VANCOUVER, British Columbia, March 3, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core...
Read more